<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531904</url>
  </required_header>
  <id_info>
    <org_study_id>CNV_2019_01</org_study_id>
    <nct_id>NCT04531904</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter</brief_title>
  <acronym>PERFECT</acronym>
  <official_title>Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter for Neurothrombectomy: A Post-Market Clinical Follow-up Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerenovus, Part of DePuy Synthes Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerenovus, Part of DePuy Synthes Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke&#xD;
      patients with confirmed intracranial large vessel occlusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PERFECT Study is a prospective, multi-center, single arm, post-market clinical follow-up&#xD;
      study.&#xD;
&#xD;
      The objective of this post-market clinical follow-up study is to assess the performance of&#xD;
      the EMBOVAC Aspiration Catheter in the treatment of acute ischemic stroke in a real-world&#xD;
      clinical setting.&#xD;
&#xD;
      The study will also report on clot characteristics and clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Successful Revascularization</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful Revascularization without rescue</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Revascularization</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Pass Effect</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recanalization</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>90 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related serious adverse events</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracerebral Hemorrhage at 24 hours</measure>
    <time_frame>24 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS at 24 hours</measure>
    <time_frame>24 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 Day all-cause mortality</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalization length of stay</measure>
    <time_frame>90 Days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare resource utilization</measure>
    <time_frame>90 Days</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMBOVAC Aspiration Catheter</intervention_name>
    <description>The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. . The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Clot / Thrombus&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute Ischemic Stroke patients with confirmed intracranial large vessel occlusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject ≥ 18 years old.&#xD;
&#xD;
          2. Subject experiencing acute ischemic stroke with angiographic confirmation of Large&#xD;
             Vessel Occlusion of the distal intracranial internal carotid artery, middle cerebral&#xD;
             artery or anterior cerebral artery.&#xD;
&#xD;
          3. A clinical decision has been made to use the EmboVac™ aspiration catheter prior to&#xD;
             enrollment in the research.&#xD;
&#xD;
          4. EmboVac™ Aspiration Catheter is used for the first 3 clot removal passes for the&#xD;
             target intracranial occlusion&#xD;
&#xD;
          5. Pre-stroke mRS ≤ 1&#xD;
&#xD;
          6. NIHSS ≤ 30&#xD;
&#xD;
          7. Subject or subject's legally authorized representative has signed and dated an&#xD;
             Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Potential study candidate has already undergone standard of care assessments or&#xD;
             treatment that deviate from the clinical research protocol requirements.&#xD;
&#xD;
          2. All patients with severe hypertension on presentation. All patients, in whom&#xD;
             intravenous therapy with blood pressure medications is indicated, with hypertension&#xD;
             that remains severe and sustained despite intravenous antihypertensive therapy.&#xD;
&#xD;
          3. Known cerebral vasculitis.&#xD;
&#xD;
          4. Known cancer with life expectancy less than 12 months&#xD;
&#xD;
          5. Stenosis, or any occlusion, in a proximal vessel that requires treatment or prevents&#xD;
             access to the site of occlusion&#xD;
&#xD;
          6. Intracranial stenosis that prevents access to the site of occlusion.&#xD;
&#xD;
          7. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh&#xD;
             hemorrhage on presentation.&#xD;
&#xD;
          8. Baseline computed tomography (CT) or MRI showing mass effect or intracranial tumor&#xD;
             (except small meningioma).&#xD;
&#xD;
          9. Evidence of dissection in the extra or intracranial cerebral arteries.&#xD;
&#xD;
         10. Occlusions in multiple vascular territories.&#xD;
&#xD;
         11. Confirmation of positive pregnancy test according to site specific standard of care.&#xD;
&#xD;
         12. Currently participating in an investigational clinical trial that may confound study&#xD;
             endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Lobotesis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maeve Holian</last_name>
    <phone>+353 91 394123</phone>
    <email>mholian1@its.jnj.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnaud Nicolas</last_name>
    <email>ANICOLAS@ITS.JNJ.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Eckert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyriakos Lobotesis</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>perfect</keyword>
  <keyword>embovac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

